Summary
La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company, which discovers, develops and markets pharmaceutical products for life threatening diseases. Its product pipeline includes GCS-100, a galectin-3 inhibitor for the treatment of chronic kidney disease; LJPC-501, a proprietary formulation of angiotensin II for catecholamine-resistant hypotension and hepatorenal syndrome; and LJPC-401, a formulation of hepcidin for hemochromatosis and beta thalassemia. The company also develops two next-generation gentamicin derivatives, namely, LJPC-30Sa and LJPC-30Sb for the treatment of serious bacterial infections and rare genetic disorders such as Duchenne muscular dystrophy and cystic fibrosis. La Jolla is headquartered in San Diego, California, the US.
La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
La Jolla Pharmaceutical Company, Medical Devices Deals, 2010 to YTD 2016 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
La Jolla Pharma Acquires Rights Of Regenerative Immunophilin Ligand Compounds From GliaMed 15
Merger 16
La Jolla Pharma Terminates Merger With Adamis Pharma 16
Licensing Agreements 18
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 18
IURTC Enters into Licensing Agreement with La Jolla Pharma 19
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 20
La Jolla Pharma Enters into Licensing Agreement with George Washington University 21
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 22
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 23
Equity Offering 24
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharma Completes Private Placement Of US$5 Million 30
La Jolla Pharma Completes Private Placement Of US$0.87 Million 31
La Jolla Pharma Completes Private Placement Of US$5.13 Million 32
La Jolla Pharmaceutical Company - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2015 1
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
La Jolla Pharmaceutical Company, Deals By Therapy Area, 2010 to YTD 2016 8
La Jolla Pharmaceutical Company, Medical Devices Deals, 2010 to YTD 2016 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
La Jolla Pharma Acquires Rights Of Regenerative Immunophilin Ligand Compounds From GliaMed 15
La Jolla Pharma Terminates Merger With Adamis Pharma 16
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 18
IURTC Enters into Licensing Agreement with La Jolla Pharma 19
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 20
La Jolla Pharma Enters into Licensing Agreement with George Washington University 21
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 22
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharma Completes Private Placement Of US$5 Million 30
La Jolla Pharma Completes Private Placement Of US$0.87 Million 31
La Jolla Pharma Completes Private Placement Of US$5.13 Million 32
La Jolla Pharmaceutical Company, Key Competitors 34
La Jolla Pharmaceutical Company, Key Employees 35
La Jolla Pharmaceutical Company, Subsidiaries 36
List of Figures
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
La Jolla Pharmaceutical Company, Medical Devices Deals, 2010 to YTD 2016 10
